Akeso: China's NMPA Accepts Ivonescimab + Chemo SNDA As First-Line Treatment For Advanced Sq-NSCLC

Akeso Inc. (AKESF) announced China's National Medical Products Administration (NMPA) accepted a supplementary New Drug Application (sNDA) for its PD-1/VEGF bispecific antibody, ivonescimab, for first-line treatment of advanced squamous non-small cell lung cancer (sq-NSCLC) in combination with chemotherapy. This acceptance, based on positive Phase III HARMONi-6 study results demonstrating superiority over existing treatments, marks the third regulatory approval for ivonescimab in China and reinforces its expanding global footprint with over 12 ongoing registrational/Phase III trials across various cancer types.

Analysis

Akeso Inc. has achieved a significant regulatory milestone with China's National Medical Products Administration (NMPA) accepting its supplementary New Drug Application for ivonescimab. This application, for the first-line treatment of advanced squamous non-small cell lung cancer (sq-NSCLC), is underpinned by the Phase III HARMONi-6 study, which demonstrated superiority over existing treatments. This marks the third regulatory acceptance for ivonescimab in China, indicating a strong and positive relationship with the regulator and validating the drug's efficacy profile. The broader context reveals a robust and expanding clinical program, with ivonescimab currently in over 12 registrational/Phase III trials globally, including six head-to-head studies against established PD-1/L1 inhibitors. This extensive pipeline, targeting a wide range of malignancies from lung to colorectal and breast cancer, positions ivonescimab as a potential blockbuster asset with a significant global market opportunity, mitigating reliance on a single indication.

Key Decisions for Investors

• The consistent regulatory progress in China, supported by superior Phase III data, significantly de-risks the commercial pathway for ivonescimab and reinforces the asset's potential to become a standard-of-care treatment.
• Investors should closely monitor upcoming data readouts from the extensive global trial program, as positive results in additional indications could serve as major catalysts and substantially expand the drug's total addressable market.
• Given the drug's advancement in multiple cancer types and head-to-head trials, it is prudent to assess Akeso's competitive positioning against established players in the immunotherapy space, as ivonescimab appears to be building a strong evidence-based case for superiority.